<DOC>
	<DOCNO>NCT00006092</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient recurrent refractory acute lymphoblastic leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Induction Therapy Adult Patients With Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate clinical hematologic response patient Philadelphia chromosome-positive recurrent refractory acute lymphoblastic leukemia previously untreated recurrent refractory blastic phase chronic myelogenous leukemia treat arsenic trioxide . - Determine duration hematologic response overall survival patient treat regimen . - Determine pattern clinical adverse experience patient treat regimen . - Determine pharmacokinetic profile regimen patient . OUTLINE : This multicenter study . Patients receive arsenic trioxide IV 2-3 hour daily 28 day . Patients respond may receive second course therapy begin 28 day last dose first course . Patients follow monthly 3 month , every 2 month 6 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 24-49 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute lymphoblastic leukemia Philadelphia chromosome ( Bcrabl ) positive Refractory initial therapy OR recurrent follow 1 induction therapy regimen without consolidation therapy and/or bone marrow transplantation Blastic phase chronic myelogenous leukemia Philadelphia chromosome ( Bcrabl ) positive Previously untreated OR recurrent refractory follow 1 induction therapy regimen without consolidation therapy include imatinib mesylate Must eligible bone marrow transplant PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : At least 8 week Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 time upper limit normal ( ULN ) AST/ALT great 2 time ULN Renal : Creatinine great 2.0 time ULN Creatinine clearance great 70 mL/min Cardiovascular : No uncontrolled angina No New York Heart Association class III IV heart disease No second degree heart block without pacemaker Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study HIV negative No uncontrolled infection serious concurrent illness No peripheral neuropathy No potassium le 3.0 great 5.5 mEq/L correct OR No magnesium le 1.2 great 2.5 mEq/L correct Electrolyte imbalance must correct prior study entry PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 28 day since prior chemotherapy At least 24 hour since prior hydroxyurea No prior arsenic trioxide No concurrent cytotoxic chemotherapy except intrathecal chemotherapy CNS leukemia Endocrine therapy : Not specify Radiotherapy : At least 28 day since prior radiotherapy No concurrent radiotherapy include palliation Surgery : Not specify Other : At least 14 day since prior imatinib mesylate No concurrent investigational agent No concurrent amphotericin B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>lymphoid leukemia</keyword>
	<keyword>myeloid monocytic leukemia</keyword>
</DOC>